instruction:
Given a passage with a question and an answer to that question, classify if the answer actually answers the question into 'yes' or 'no'. Output 'yes' if the answer answers the question and output 'no' if the answer does not answer the question.
question:
Question: Has survival after recurrent esophageal carcinoma improved over the past 18 years?
Answer: Survival after recurrent EC in patients who undergo FU without routine imaging after esophagectomy is approximately 3 months and has not improved over the past 18 years.
answer:
no


question:
Question: Are the Randomized Olmesartan and Diabetes Microalbuminuria Prevention ( ROADMAP ) observational follow-up study : benefits of RAS blockade with olmesartan treatment sustained after study discontinuation?
Answer: Development of microalbuminuria is a valid marker for future CV events. RAS blockade with Olmesartan might cause sustained reduction (legacy effect) of micro- and macrovascular events.
answer:
yes


question:
Question: Does interferon responsiveness change in treatment-experienced hepatitis C subjects : implications for drug development and clinical decisions?
Answer: We contend that P/R-experienced subjects are represented within treatment-naive subjects. There are 2 important implications of this finding: (1) from a drug development perspective, a successful direct antiviral plus P/R therapy (IFN-based triple therapy) trial in P/R-experienced subjects may serve as supportive evidence in treatment-naive subjects; and (2) from a clinical decision perspective, previous P/R exposure should not alter new treatment decisions involving IFN-based triple therapy, as the IFN responsiveness to a second course of IFN is comparable.
answer:

no